Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, February 25, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tiago Fauth Maintained (ABCL) at Buy with Increased Target to $40 on, Feb 25th, 2022
Tiago Fauth of Credit Suisse, Maintained "AbCellera Biologics Inc." (ABCL) at Buy with Increased Target from $39 to $40 on, Feb 25th, 2022.
Tiago has made no other calls on ABCL in the last 4 months.
There are 2 other peers that have a rating on ABCL. Out of the 2 peers that are also analyzing ABCL, 0 agree with Tiago's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Tiago
- Robert Wasserman of "Benchmark" Initiated at Strong Buy and Held Target at $27 on, Tuesday, December 21st, 2021
- Do Kim of "Piper Sandler" Initiated at Buy and Held Target at $33 on, Friday, November 19th, 2021
